Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab

NCT05767021 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05767021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
May 17, 2023
Completion date
April 27, 2026
Enrollment
172 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis, ulcerative colitis chronic